

# JOHNSON & JOHNSON

ISIN: US4781601046 WKN: 478160104 Asset Class: Stock

**Company** 2024/07/26 22:00:02

**Price**  
 **160.64**  
 USD

**Difference**  0.63%(1.00)



**Contact Details**

JOHNSON & JOHNSON Tel: +1-732-524-0400  
 -- Fax: +  
 One Johnson & Johnson Plaza Web: <http://www.jnj.com>  
 08933 New Brunswick E-mail: -

## Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	53,495,000,000		55,294,000,000		60,979,000,000	
<b>Common stock capital</b>		3,120,000,000		3,120,000,000		3,120,000,000
<b>Fixed assets</b>	114,063,000,000		132,084,000,000		121,039,000,000	
<b>Equity capital of a company</b>		68,774,000,000		76,804,000,000		74,023,000,000
<b>Cash and cash equivalents</b>	21,859,000,000		14,127,000,000		14,487,000,000	
<b>Accrued liabilities</b>		7,149,000,000		6,767,000,000		8,898,000,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		46,282,000,000		55,802,000,000		45,226,000,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		52,502,000,000		54,772,000,000		62,769,000,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		15,179,000,000		13,443,000,000		15,399,000,000
<b>Total assets</b>	167,558,000,000	167,558,000,000	187,378,000,000	187,378,000,000	182,018,000,000	182,018,000,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	US-GAAP	US-GAAP	US-GAAP
<b>Employees</b>	131,900	152,700	141,700
<b>Equity ratio</b>	41.04%	40.99%	40.67%
<b>Debt-equity ratio</b>	143.64%	143.97%	145.89%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	11.53%	17.42%	8.33%

# JOHNSON & JOHNSON

ISIN: US4781601046 WKN: 478160104 Asset Class: Stock

## Income statement

	2023	2022	2021
Turnover	85,152,000,000	95,015,000,000	93,758,000,000
Net income	13,326,000,000	17,941,000,000	20,878,000,000
EBIT	13,869,741,600	20,392,612,500	21,688,522,700
Operating income before taxes	15,062,000,000	21,725,000,000	22,776,000,000
Cash Flow	22,791,000,000	21,194,000,000	23,410,000,000
Net interest income	14,000,000	-400,000,000	-755,000,000
Research and development expenses	15,048,000,000	14,752,000,000	14,744,000,000
Income taxes	1,736,000,000	3,784,000,000	1,898,000,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	595,031	573,512	609,857

## Board of Directors

## Members of Management Board

Jennifer Doudna	Member of Board of Directors
Mark McClellan	Member of Board of Directors
Mary Beckerle	Member of Board of Directors
Nadja West	Member of Board of Directors
Paula Johnson	Member of Board of Directors
Anne Mulcahy	Member of Board of Directors
D. Davis	Member of Board of Directors
Darius Adamczyk	Member of Board of Directors
Eugene Woods	Member of Board of Directors
Hubert Joly	Member of Board of Directors
Marilyn Hewson	Member of Board of Directors
Mark Weinberger	Member of Board of Directors
Joaquin Duato	Chairman of Managing Board
James Swanson	Member of Executive Committee
Jennifer Taubert	Member of Executive Committee
Joseph J. Wolk	Member of Executive Committee
Kathy Wengel	Member of Executive Committee
Liz Forminard	Member of Executive Committee
Peter M. Fasolo	Member of Executive Committee
Vanessa Broadhurst	Member of Executive Committee
William N. Hait	Member of Executive Committee